# Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Canonical URL: https://biopharmsignal.com/news/JAGX/jaguar-health-announces-preliminary-discussion-with-fda-to-evaluate-breakthrough-therapy-designation-for-crofelemer-for-treatment-of-microvillus-inclusion-disease-mvid
Ticker: JAGX
Company: Jaguar Health
Source: Jaguar Health
Published: 2026-05-06 13:00 EST
Original Source URL: https://jaguarhealth.gcs-web.com
## Summary

Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (PS), could benefit from expedited development of oral crofelemer via Breakthrough Therapy

## Article Body
Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (PS), could benefit from expedited development of oral crofelemer via Breakthrough Therapy
## Recent Company News
- 2026-05-28 14:00 EST — [Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders](https://biopharmsignal.com/news/JAGX/jaguar-health-research-in-ethnobotanical-medicine-helps-advance-crofelemer-development-for-genetically-defined-rare-congenital-gastrointestinal-disorders) — Source: Jaguar Health
- 2026-05-27 13:00 EST — [Jaguar Health Compliant with Nasdaq Bid Price Rule](https://biopharmsignal.com/news/JAGX/jaguar-health-compliant-with-nasdaq-bid-price-rule) — Source: Jaguar Health
- 2026-05-20 20:40 EST — [Jaguar Health Reports First Quarter 2026 Financials](https://biopharmsignal.com/news/JAGX/jaguar-health-reports-first-quarter-2026-financials) — Source: Jaguar Health
- 2026-05-20 13:00 EST — [Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference](https://biopharmsignal.com/news/JAGX/jaguar-health-to-hold-investor-webcast-may-26-regarding-q1-2026-financials-and-corporate-updates-jaguar-ceo-lisa-conte-presenting-may-28-at-lytham-partners-spring-2026-investor-conference) — Source: Jaguar Health
- 2026-05-19 13:00 EST — [Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer](https://biopharmsignal.com/news/JAGX/jaguar-health-announces-active-treatment-only-continuation-of-pivotal-multicenter-clinical-trial-in-pediatric-patients-with-microvillus-inclusion-disease-mvid-to-support-a-new-drug-application-nda-for-liquid-oral-crofelemer) — Source: Jaguar Health
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)